Repare Therapeutics

Repare Therapeutics EBIT

Delisted

The EBIT of Repare Therapeutics (RPTX) as of Oct 24, 2026 is -93.52 M USD. In the previous year, EBIT was -116.22 M USD — a change of -19.53% (higher).

EBIT

-93.52 MUSD

YoY

-19.53%

Last updated:

In 2024, Repare Therapeutics's EBIT was -93.52 M USD, a -19.53% increase from the -116.22 M USD EBIT recorded in the previous year.

The Repare Therapeutics EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2022
-19.80 M USD
Jan 1, 2023
-116.22 M USD
Jan 1, 2024
-93.52 M USD
Jan 1, 2025 (e)
-249,009.00 USD
Jan 1, 2026 (e)
-5.53 M USD
Jan 1, 2027 (e)
-7.81 M USD
Jan 1, 2028 (e)
-12.45 M USD
Jan 1, 2029 (e)
-116.20 M USD
The Repare Therapeutics EBIT history
YEAREBITYoY
est-116.20 MUSD+833.33%
est-12.45 MUSD+59.46%
est-7.81 MUSD+41.10%
est-5.53 MUSD+2,122.23%
est-249,009.00USD-99.73%
-93.52 MUSD-19.53%
-116.22 MUSD+487.11%
-19.80 MUSD-81.78%
-108.66 MUSD+100.10%
-54.30 MUSD+110.38%
-25.81 MUSD+101.33%
-12.82 MUSD+107.61%
-6.18 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Repare Therapeutics Revenue

Repare Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
131.83 M USD
-19.80 M USD
-29.05 M USD
Jan 1, 2023
51.13 M USD
-116.22 M USD
-93.80 M USD
Jan 1, 2024
53.48 M USD
-93.52 M USD
-84.69 M USD
Jan 1, 2025 (e)
300,000.00 USD
-249,009.00 USD
-74.37 M USD
Jan 1, 2026 (e)
6.67 M USD
-5.53 M USD
-54.17 M USD
Jan 1, 2027 (e)
9.41 M USD
-7.81 M USD
-25.79 M USD
Jan 1, 2028 (e)
15.00 M USD
-12.45 M USD
-25.79 M USD
Jan 1, 2029 (e)
140.00 M USD
-116.20 M USD
-27.94 M USD

Repare Therapeutics Margins

Repare Therapeutics stock margins

The Repare Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Repare Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Repare Therapeutics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
11.46 %
-15.02 %
-22.03 %
Jan 1, 2023
74.11 %
-227.30 %
-183.44 %
Jan 1, 2024
74.98 %
-174.88 %
-158.37 %
Jan 1, 2025 (e)
74.98 %
-83.00 %
-24,790.90 %
Jan 1, 2026 (e)
74.98 %
-83.00 %
-812.51 %
Jan 1, 2027 (e)
74.98 %
-83.00 %
-274.21 %
Jan 1, 2028 (e)
74.98 %
-83.00 %
-171.96 %
Jan 1, 2029 (e)
74.98 %
-83.00 %
-19.96 %

Repare Therapeutics Stock analysis

What does Repare Therapeutics do? Repare Therapeutics Inc is a biotechnology company specializing in the development of precision medicines for the treatment of cancer. It was founded in 2016 by four leading scientists and is headquartered in Montreal, Canada. The company utilizes an innovative and unique approach called CRISPR-Cas9 to identify and target genetic mutations in cancer cells. The history of Repare Therapeutics Inc stems from a collaboration among renowned cancer researchers. In 2016, the founders, who already had extensive experience in drug development, pooled their resources to create a new generation of cancer therapies. Using the innovative CRISPR-Cas9 system, they were able to specifically identify genetic alterations in cancer cells and significantly reduce tumor burden. Since its inception, the company has formed strong partnerships and successfully raised capital to continue its research and development. Repare Therapeutics has a unique business model focused on developing precision medicine for patients with specific types of cancer. The company combines CRISPR-Cas technology and machine learning to identify genetic mutations in cancer cells and correlate them with an extensive dataset of available clinical studies. This systematic approach allows for faster and more precise identification of suitable target molecules that may serve as potential therapy options for cancer. Repare Therapeutics specializes in quickly and efficiently developing molecules that target these target molecules and advancing them through clinical trials. The company distributes its precision medicines in three different sectors: oncology, therapeutics, and research. The oncology sector specializes in the development of precision medicines for the treatment of cancer. The therapeutics sector offers solutions for the medical care of patients through the development of novel therapies. The research department focuses on developing new precision medicines and advancing innovations in cancer research. Repare Therapeutics offers various products tailored to the needs of cancer patients. The CRISPR-Cas9 technology is being used to advance multiple clinical programs aimed at regulating gene expression in tumor cells and enhancing the effectiveness of cancer therapies. The company's flagship product, RP-3500, is a precision medicine specifically targeted against a gene called KRAS, which plays a crucial role in many types of cancer. The medication has demonstrated strong efficacy in clinical trials and is currently in Phase 1 studies. In summary, Repare Therapeutics Inc is an innovative biotechnology company specializing in the development of precision medicines against cancer. The use of CRISPR-Cas9 technology in combination with machine learning allows for faster identification of suitable target molecules that may serve as potential therapy options for cancer. The company offers various precision medicines that benefit cancer patients. With its numerous research programs and clinical trials, Repare Therapeutics is poised to become a leading player in cancer treatment and research. Repare Therapeutics is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Repare Therapeutics's EBIT

Repare Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Repare Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Repare Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Repare Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Repare Therapeutics stock

EBIT of Repare Therapeutics is -93.52 M USD in 2024.

EBIT of Repare Therapeutics changed from -116.22 M USD to -93.52 M USD, representing a -19.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Repare Therapeutics since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Repare Therapeutics historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Repare Therapeutics

All Key Metrics — Repare Therapeutics